Results 231 to 238 of about 65,998 (238)

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types

Annals of Oncology, 2020
exaly  

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Lancet, The
Eray Goekkurt, Lixian Jin, Steven I Blum   +2 more
exaly  

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of Thoracic Oncology, 2018
Rosalyn Juergens, Naiyer A Rizvi, Matthew Hellmann   +2 more
exaly  

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Journal of Thoracic Oncology, 2018
Hidetoshi Hayashi
exaly  

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

Cancer Medicine, 2019
Ho Yeong Lim, Jeeyun Lee, Jeong Il Yu
exaly  

Nivolumab

Reactions Weekly, 2016
openaire   +1 more source

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Annals of Oncology
JOSÉ Mauricio Mota, Laurence Albiges, B Zurawski   +2 more
exaly  

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective

Annals of Oncology, 2019
exaly